These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 21837731)

  • 1. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.
    Cucchetti A; Cescon M; Bigonzi E; Piscaglia F; Golfieri R; Ercolani G; Cristina Morelli M; Ravaioli M; Daniele Pinna A
    Liver Transpl; 2011 Nov; 17(11):1344-54. PubMed ID: 21837731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.
    Graziadei IW; Sandmueller H; Waldenberger P; Koenigsrainer A; Nachbaur K; Jaschke W; Margreiter R; Vogel W
    Liver Transpl; 2003 Jun; 9(6):557-63. PubMed ID: 12783395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma.
    Millonig G; Graziadei IW; Freund MC; Jaschke W; Stadlmann S; Ladurner R; Margreiter R; Vogel W
    Liver Transpl; 2007 Feb; 13(2):272-9. PubMed ID: 17256758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.
    Pelletier SJ; Fu S; Thyagarajan V; Romero-Marrero C; Batheja MJ; Punch JD; Magee JC; Lok AS; Fontana RJ; Marrero JA
    Liver Transpl; 2009 Aug; 15(8):859-68. PubMed ID: 19642139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.
    Maddala YK; Stadheim L; Andrews JC; Burgart LJ; Rosen CB; Kremers WK; Gores G
    Liver Transpl; 2004 Mar; 10(3):449-55. PubMed ID: 15004776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.
    Yao FY; Bass NM; Nikolai B; Davern TJ; Kerlan R; Wu V; Ascher NL; Roberts JP
    Liver Transpl; 2002 Oct; 8(10):873-83. PubMed ID: 12360427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria.
    Herrero JI; Sangro B; Pardo F; Quiroga J; Iñarrairaegui M; Rotellar F; Montiel C; Alegre F; Prieto J
    Liver Transpl; 2008 Mar; 14(3):272-8. PubMed ID: 18306328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
    Park SJ; Freise CE; Hirose R; Kerlan RK; Yao FY; Roberts JP; Vagefi PA
    Clin Transplant; 2012; 26(4):E359-64. PubMed ID: 22693962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.
    Lu DS; Yu NC; Raman SS; Lassman C; Tong MJ; Britten C; Durazo F; Saab S; Han S; Finn R; Hiatt JR; Busuttil RW
    Hepatology; 2005 May; 41(5):1130-7. PubMed ID: 15841454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Huang YH; Su CW; Lin HC; Chiang JH; Chiou YY; Huo SC; Lee PC; Lee SD
    Clin Transplant; 2008; 22(4):469-75. PubMed ID: 18318736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list.
    Fisher RA; Maluf D; Cotterell AH; Stravitz T; Wolfe L; Luketic V; Sterling R; Shiffman M; Posner M
    Clin Transplant; 2004 Oct; 18(5):502-12. PubMed ID: 15344951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma.
    Sandroussi C; Dawson LA; Lee M; Guindi M; Fischer S; Ghanekar A; Cattral MS; McGilvray ID; Levy GA; Renner E; Greig PD; Grant DR
    Transpl Int; 2010 Mar; 23(3):299-306. PubMed ID: 19843294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current controversies surrounding liver transplantation for hepatocellular carcinoma.
    Silva MF; Wigg AJ
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1217-26. PubMed ID: 20594247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for liver transplantation.
    Yamashiki N; Tateishi R; Yoshida H; Shiina S; Teratani T; Sato S; Mine N; Kondo Y; Kawabe T; Omata M
    Liver Transpl; 2005 May; 11(5):508-14. PubMed ID: 15838878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States.
    Kadry Z; Schaefer EW; Uemura T; Shah AR; Schreibman I; Riley TR
    J Hepatol; 2012 Mar; 56(3):618-25. PubMed ID: 22027581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.